Zhengye Biotechnology Holding (ZYBT) Other Non-Current Liabilities (2024)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Other Non-Current Liabilities of $20325.5 for Q4 2024.
Zhengye Biotechnology Holding (ZYBT) Other Non-Current Liabilities (2024) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Other Non-Current Liabilities for 1 consecutive years, with $20325.5 the latest figure, recorded in Q4 2024.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $20325.5 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $20325.5 (changed N/A YoY) and the FY2024 annual result came in at $20000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $20325.5 in Q4 2024 per ZYBT's latest filing.
- Over the last five years, Other Non-Current Liabilities for ZYBT reached as high as $20325.5 in Q4 2024 and fell as low as $20325.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Zhengye Biotechnology Holding | 85.23 Mn | 85.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20,325.50 |